Literature DB >> 15450572

Reverse cardiac remodelling in patients with primary pulmonary hypertension after isolated lung transplantation.

Marie-Theres Kasimir1, Gernot Seebacher, Peter Jaksch, Günther Winkler, Katharina Schmid, Gabriel M Marta, Paul Simon, Walter Klepetko.   

Abstract

OBJECTIVE: Pulmonary hypertension eventually leads to severe distortion of the cardiac geometry with consequent impact on cardiac function. The purpose of this study was to prove reverse cardiac remodelling after isolated bilateral lung transplantation (LuTX) in patients with advanced primary pulmonary hypertension (PPH) and severe alterations of cardiac morphology and function.
METHODS: In the period of 2000-2002 17 (10 female, seven male) patients with advanced PPH underwent isolated bilateral LuTX. Median age was 30 years (range 16-53). All patients were in NYHA III or IV, most of them with intractable ascites, established renal impairment, malnutrition and immobility, continuously deteriorating despite various forms of pharmacological treatment including i.v. and inhalative prostacyclin, diuretics, Ca-antagonists, bosentan and catecholamines. Echocardiography and Doppler echocardiography measurements were performed before and 3 months after transplantation. Left and right ventricular diameters and function were assessed and tricuspid valve regurgitation was determined.
RESULTS: Mortality after 3 months was 17.5% (cerebral bleeding, multi-organ failure and diffuse myocardial infarction in one patient each). Three months after LuTX the 14 surviving patients were in NYHA I or II. Echocardiography showed normal left ventricular function and markedly improved right ventricular function with normal size of the RV. The leftward shifted flattened interventricular septum had returned in its physiological position and the high-grade tricuspid insufficiency had disappeared in all patients.
CONCLUSIONS: Advanced alterations of cardiac morphology and function normalize completely and pre-existing tricuspid insufficiency disappears in PPH patients after isolated bilateral LuTX. Quality of life is excellent. Therefore, LuTX is preferred and safe in patients with advanced PPH even with severe cardiac dysfunction.

Entities:  

Mesh:

Year:  2004        PMID: 15450572     DOI: 10.1016/j.ejcts.2004.05.057

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  23 in total

1.  Subharmonic microbubble emissions for noninvasively tracking right ventricular pressures.

Authors:  Jaydev K Dave; Valgerdur G Halldorsdottir; John R Eisenbrey; Joel S Raichlen; Ji-Bin Liu; Maureen E McDonald; Kris Dickie; Shumin Wang; Corina Leung; Flemming Forsberg
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-05-04       Impact factor: 4.733

2.  Long-term animal model of venovenous extracorporeal membrane oxygenation with atrial septal defect as a bridge to lung transplantation.

Authors:  Daniele Camboni; Alvaro Rojas; Peter Sassalos; David Spurlock; Kelly L Koch; Sarah Menchak; Jennifer Singleton; Erika Boothman; Jonathan W Haft; Robert H Bartlett; Keith E Cook
Journal:  ASAIO J       Date:  2013 Nov-Dec       Impact factor: 2.872

Review 3.  Stem and progenitor cell therapy for pulmonary arterial hypertension: effects on the right ventricle (2013 Grover Conference Series).

Authors:  Arnoud van der Laarse; Christa M Cobbaert; Soban Umar
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

4.  Combining tricuspid valve repair with double lung transplantation in patients with severe pulmonary hypertension, tricuspid regurgitation, and right ventricular dysfunction.

Authors:  Norihisa Shigemura; Basar Sareyyupoglu; Jay Bhama; Pramod Bonde; Jnanesh Thacker; Christian Bermudez; Cynthia Gries; Maria Crespo; Bruce Johnson; Joseph Pilewski; Yoshiya Toyoda
Journal:  Chest       Date:  2011-06-23       Impact factor: 9.410

5.  Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension.

Authors:  Shannon E Blalock; Susan Matulevicius; Laura C Mitchell; Sharon Reimold; John Warner; Ronald Peshock; Fernando Torres; Kelly M Chin
Journal:  J Card Fail       Date:  2009-11-20       Impact factor: 5.712

6.  Delineating the molecular and histological events that govern right ventricular recovery using a novel mouse model of pulmonary artery de-banding.

Authors:  Mario Boehm; Xuefei Tian; Yuqiang Mao; Kenzo Ichimura; Melanie J Dufva; Khadem Ali; Svenja Dannewitz Prosseda; Yiwei Shi; Kazuya Kuramoto; Sushma Reddy; Vitaly O Kheyfets; Ross J Metzger; Edda Spiekerkoetter
Journal:  Cardiovasc Res       Date:  2020-08-01       Impact factor: 10.787

7.  Cardiovascular magnetic resonance in pulmonary hypertension.

Authors:  William M Bradlow; J Simon R Gibbs; Raad H Mohiaddin
Journal:  J Cardiovasc Magn Reson       Date:  2012-01-18       Impact factor: 5.364

8.  Pulmonary hypertension before first and second lung transplantation.

Authors:  Adriano R Tonelli; Irina Timofte; Omar A Minai; Maher Baz; Olufemi Akindipe
Journal:  Clin Transplant       Date:  2012-02-10       Impact factor: 2.863

9.  Pharmacological Inhibition of mTOR Kinase Reverses Right Ventricle Remodeling and Improves Right Ventricle Structure and Function in Rats.

Authors:  Andressa Pena; Ahasanul Kobir; Dmitry Goncharov; Akiko Goda; Tatiana V Kudryashova; Arnab Ray; Rebecca Vanderpool; Jeffrey Baust; Baojun Chang; Ana L Mora; John Gorcsan; Elena A Goncharova
Journal:  Am J Respir Cell Mol Biol       Date:  2017-11       Impact factor: 6.914

10.  Prognostic value of pre-transplant mean pulmonary arterial pressure in lung transplant recipients: a single-institution experience.

Authors:  Chi Young Kim; Ji Eun Park; Ah Young Leem; Joo Han Song; Song Yee Kim; Kyung Soo Chung; Eun Young Kim; Ji Ye Jung; Young Ae Kang; Young Sam Kim; Joon Chang; Jin Gu Lee; Hyo Chae Paik; Moo Suk Park
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.